Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease

Recruiting now · Phase 1

Conditions studied: Parkinson's Disease

In brief

This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.

Key facts

Study ID
NCT05901818
Run by
Xuanwu Hospital, Beijing
People needed
6
Starts
2021-04-01
Expected to finish
2028-12-31
Last updated by the study team
2026-07-01

Who can join

Age: 30 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.